Quetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder: a double-blind, randomised, placebo-controlled study [ISRCTN83050762]
1 MRC Research Unit on Anxiety Disorders, University of Stellenbosch, Cape Town, South Africa
2 Department of Psychiatry and Behavioral Neurosciences, McMaster University, Hamilton, Ontario, Canada
BMC Psychiatry 2005, 5:44 doi:10.1186/1471-244X-5-44Published: 30 November 2005
First paragraph (this article has no abstract)
The comment in the introduction of our article  suggesting that "quetiapine is the only available antipsychotic with significant 5-HT1D effects," is misleading. The affinity of quetiapine for this receptor is low and probably insignificant when compared with some other second generation antipsychotics .